SG11201501043TA - Pharmaceutical composition for oral administration with improved dissolution and/or absorption - Google Patents

Pharmaceutical composition for oral administration with improved dissolution and/or absorption

Info

Publication number
SG11201501043TA
SG11201501043TA SG11201501043TA SG11201501043TA SG11201501043TA SG 11201501043T A SG11201501043T A SG 11201501043TA SG 11201501043T A SG11201501043T A SG 11201501043TA SG 11201501043T A SG11201501043T A SG 11201501043TA SG 11201501043T A SG11201501043T A SG 11201501043TA
Authority
SG
Singapore
Prior art keywords
absorption
pharmaceutical composition
oral administration
improved dissolution
dissolution
Prior art date
Application number
SG11201501043TA
Other languages
English (en)
Inventor
Takashi Suefuji
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG11201501043TA publication Critical patent/SG11201501043TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
SG11201501043TA 2012-09-19 2013-09-18 Pharmaceutical composition for oral administration with improved dissolution and/or absorption SG11201501043TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012205681 2012-09-19
PCT/JP2013/075157 WO2014046129A1 (ja) 2012-09-19 2013-09-18 溶出性及び/又は吸収性が改善された経口投与用医薬組成物

Publications (1)

Publication Number Publication Date
SG11201501043TA true SG11201501043TA (en) 2015-04-29

Family

ID=50341439

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501043TA SG11201501043TA (en) 2012-09-19 2013-09-18 Pharmaceutical composition for oral administration with improved dissolution and/or absorption

Country Status (20)

Country Link
US (1) US9555115B2 (es)
EP (1) EP2898886B1 (es)
JP (1) JP5791817B2 (es)
KR (1) KR101609105B1 (es)
CN (1) CN104640547B (es)
AU (1) AU2013319118B2 (es)
BR (1) BR112015005489B1 (es)
CA (1) CA2884731C (es)
DK (1) DK2898886T3 (es)
ES (1) ES2622585T3 (es)
HK (1) HK1207969A1 (es)
HU (1) HUE032635T2 (es)
MX (1) MX345435B (es)
MY (1) MY183976A (es)
PL (1) PL2898886T3 (es)
PT (1) PT2898886T (es)
RU (1) RU2589701C1 (es)
SG (1) SG11201501043TA (es)
TW (1) TWI536992B (es)
WO (1) WO2014046129A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI707851B (zh) * 2015-09-17 2020-10-21 日商大鵬藥品工業股份有限公司 哌嗪化合物的新穎結晶

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
TW482675B (en) 1997-01-31 2002-04-11 Green Cross Corp Compositions for oral administration containing pyridazinone compounds technical field of the invention
JP4292588B2 (ja) * 1997-01-31 2009-07-08 日産化学工業株式会社 ピリダジノン化合物類の経口製剤
JP3797764B2 (ja) 1997-10-01 2006-07-19 エーザイ株式会社 光安定化組成物
ATE528303T1 (de) * 2000-12-21 2011-10-15 Vertex Pharma Pyrazoleverbindungen als proteinkinasehemmer
EP1397160A1 (en) * 2001-04-30 2004-03-17 Shire Laboratories Inc. Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
US20040137052A1 (en) 2001-12-25 2004-07-15 Yoshihiro Uchiyama Acid-containing preparations
JP2003252762A (ja) * 2001-12-25 2003-09-10 Takeda Chem Ind Ltd 酸配合製剤
DE10209982A1 (de) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
JP4572293B2 (ja) * 2004-07-21 2010-11-04 トーアエイヨー株式会社 ピモベンダン経口投与製剤
BRPI0716196A2 (pt) * 2006-08-31 2013-11-12 Eurand Inc Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos.
BRPI0809522A2 (pt) 2007-03-28 2014-10-14 Takeda Pharmaceutical Composição farmacêutica sólida, métodos para estabilizar um composto, e para melhorar dissolução de um composto, e, uso de um agente de controle de ph.
CN101848713B (zh) * 2007-05-21 2012-04-11 东丽株式会社 含有特定的有机酸的口服制剂以及口服制剂的溶出性和化学稳定性的改善方法
EP2313096A1 (en) 2008-06-04 2011-04-27 AstraZeneca AB (Publ) New compounds v
US9186411B2 (en) 2008-07-28 2015-11-17 Takeda Pharmaceutical Company Limited Pharmaceutical composition
JP5196004B2 (ja) 2009-03-06 2013-05-15 トヨタ自動車株式会社 運転支援装置
JP5111657B2 (ja) * 2009-03-09 2013-01-09 大鵬薬品工業株式会社 プロスタグランジンd合成酵素を阻害するピペラジン化合物

Also Published As

Publication number Publication date
CA2884731C (en) 2016-11-01
AU2013319118B2 (en) 2016-03-03
CA2884731A1 (en) 2014-03-27
AU2013319118A1 (en) 2015-03-12
WO2014046129A1 (ja) 2014-03-27
RU2589701C1 (ru) 2016-07-10
US20150297722A1 (en) 2015-10-22
ES2622585T3 (es) 2017-07-06
TWI536992B (zh) 2016-06-11
BR112015005489A2 (pt) 2017-07-04
DK2898886T3 (en) 2017-03-27
PL2898886T3 (pl) 2017-06-30
KR101609105B1 (ko) 2016-04-04
JP5791817B2 (ja) 2015-10-07
BR112015005489B1 (pt) 2022-07-12
EP2898886A1 (en) 2015-07-29
HUE032635T2 (en) 2017-10-30
KR20150056827A (ko) 2015-05-27
MX345435B (es) 2017-01-30
TW201414476A (zh) 2014-04-16
JPWO2014046129A1 (ja) 2016-08-18
HK1207969A1 (en) 2016-02-19
EP2898886A4 (en) 2016-04-27
PT2898886T (pt) 2017-03-23
CN104640547A (zh) 2015-05-20
CN104640547B (zh) 2017-07-11
MX2015003410A (es) 2015-06-04
EP2898886B1 (en) 2017-02-15
MY183976A (en) 2021-03-17
US9555115B2 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
HK1205690A1 (en) Pharmaceutical composition and administration thereof
HRP20181364T1 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
HK1204564A1 (en) Topical ophthalmological pharmaceutical composition containing axitinib
HK1199821A1 (en) Oral pharmaceutical composition
HK1199822A1 (zh) 口服給藥用醫藥組合物
ZA201306395B (en) New low side effect pharmaceutical composition containing antituberculosis drugs
HK1204992A1 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
ZA201409508B (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
EP2560614A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR ADMINISTRATION
GB2504390B (en) Nutraceutical and pharmaceutical composition
ZA201505196B (en) Topical ophthalmological pharmaceutical composition containing regorafenib
HK1204289A1 (en) Topical ophthalmological pharmaceutical composition containing cediranib
HK1198910A1 (en) Pharmaceutical composition comprising ebastine and fluticasone
EP2933290A4 (en) COMPOSITION FOR COMPLEX FORMATION, COMPLEX FORMED THEREFROM, AND COMPOSITION FOR ORAL ADMINISTRATION COMPRISING SAID COMPLEX
HK1207969A1 (en) Pharmaceutical composition for oral administration with improved dissolution and or absorption
EP2926811A4 (en) ARTEMISCULAR PHARMACEUTICAL COMPOSITION, MANUFACTURE AND USE
EP2851074A4 (en) ANALGETIC PHARMACEUTICAL COMPOSITION
ZA201503799B (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine
IL233983B (en) History of thiazolidinone and pharmaceutical preparations containing them
IL234614B (en) Pharmaceutical composition and preparation method thereof
EP2979698A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
EP2529755A4 (en) PHARMACEUTICAL COMPOSITION AND PREPARATION THEREFOR FOR ORAL ADMINISTRATION